LSI 2024: CDX showcases early test-case data

Dr. Gopal Chopra presented CDX Medical Technologies at the LSI USA '24 Emerging Medtech Summit, highlighting live demos of its compact ECMO pump in action. Early test-case data from animal trials showed 14 days of continuous use with full ambulation and consistent 2 to 3 liter flow rates.

Clinical Trial Results

The animal trial data presented at LSI 2024 demonstrated significant milestones:

- 14 days continuous operation: Extended duration testing validates system reliability

- Full ambulation capability: Patients maintained complete mobility during therapy

- Consistent flow rates: Stable 2-3 liter per minute performance throughout testing period

Technology Overview

CDX is a compact, portable extracorporeal bypass pump for partial cardio-pulmonary support, adaptable to multiple circuit configurations including oxygenators. Built for mobility and speed, the system simplifies setup and expands ECMO access beyond traditional ICU settings, setting a new standard in respiratory care delivery.

Live Demonstration Impact

The live demos at the LSI USA '24 Emerging Medtech Summit showcased the practical applications of CDX's innovative approach to ECMO therapy. The presentation highlighted how the compact design enables:

Key Advantages:

- Enhanced Patient Mobility: Full ambulation during extended therapy periods

- Simplified Operations: Streamlined setup and monitoring processes

- Expanded Access: Deployment beyond traditional ICU environments

- Reliable Performance: Consistent flow rates over extended periods

Setting New Standards

The data presented reinforces CDX Medical Technologies' position as a leader in next-generation ECMO technology, demonstrating that compact, portable systems can deliver the reliability and performance required for critical respiratory support while dramatically improving patient quality of life during treatment.